Protocols

The ATTAIN-1 Phase 3 trial (Wharton et al., NEJM 2025) showed once-daily oral orforglipron produced dose-dependent mean body-weight reductions at all three approved maintenance doses versus placebo at 72 weeks. Post-hoc modelling linked the highest approved dose to a predicted 57% reduction in 10-year type 2 diabetes risk and an 18% reduction in predicted cardiovascular disease risk versus placebo.

Current evidence indicates that semaglutide is associated with a statistically significant increase in the risk of nonarteritic anterior ischemic optic neuropathy (NAION), particularly in patients with type 2 diabetes or obesity. The absolute excess risk is approximately 3–4 additional cases per 10,000 treated patients over 18 months. Tirzepatide carries a similar signal. Causality has not been established.

The 2026 narrative review by Sever, Sikiric, and colleagues in Pharmaceuticals (MDPI, 19(10):1559) positions stable gastric pentadecapeptide BPC 157 as a prototype cytoprotective agent for liver injury. Across rodent models of paracetamol toxicity, alcohol damage, CCl4 exposure, and ischemia-reperfusion, BPC 157 attenuated hepatocyte injury, reduced oxidative stress markers, and preserved endothelial integrity — matching or outperforming standard hepatoprotective agents.

The LIGHTEN Phase III trial reported 19.3% mean body-weight reduction at 48 weeks with olatorepatide 15 mg weekly in 604 Chinese adults. Investigators attribute this to olatorepatide's dual-biased receptor pharmacology, which preferentially amplifies cAMP signalling over beta-arrestin recruitment at both GLP-1R and GIPR, producing strong efficacy with a nausea rate of only 7.8% and zero GI-related discontinuations.

The 2026 first-in-human Phase I trial of GZC8072 — a once-weekly oral peptide GLP-1 receptor agonist by Gan & Lee Pharmaceuticals — is designed to answer precisely this question. The 112-participant SAD/MAD study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults and people with overweight or obesity. No efficacy data have been reported; the trial is actively enrolling.

The 2026 Yuan review in IJMS (27:2876) establishes that BPC-157's repair and analgesic effects are convergent, not parallel. The VEGFR2–Akt–eNOS axis drives both angiogenesis and nitric oxide–mediated analgesia; cytokine suppression limits tissue damage and nociceptor sensitisation simultaneously; FAK–paxillin coordinates fibroblast repair. Three shared signalling nodes explain the compound's dual pharmacology from a single 15-amino-acid sequence.

As of 2026, the human evidence for BPC-157 across pain, tendon healing, and athletic recovery is sparse and uniformly low-quality. The entire controlled human record consists of one Phase 1 tolerability study, one unpublished Phase 2 gastrointestinal trial, and a single 16-patient retrospective knee-pain case series. No completed randomised controlled trial exists for any musculoskeletal or analgesic indication.

The 2026 Matek review in Pharmaceuticals (MDPI) establishes that BPC-157 addresses osteotendinous, myotendinous, and muscle-to-bone junctional injuries through a cytoprotection framework that distinguishes it from conventional growth factors: it requires no carrier molecule, acts systemically or locally, and simultaneously targets all tissue layers at the junction rather than a single cell type.

Federal regulators have documented at least 30 patients who experienced adverse events after receiving compounded intravenous glutathione, with reactions spanning fever, rigors, hypotension, shock-like presentations, and sepsis-like syndromes. The primary driver in the most recent cluster is elevated endotoxin contamination traced to dietary supplement-grade raw material used in sterile compounding — a practice the FDA explicitly prohibits.

BPC-157 underwent two distinct regulatory events in 2026: the FDA removed it from the Category 2 significant-safety-risk list in April, and the Pharmacy Compounding Advisory Committee voted in favour of adding it to the 503A Bulks List in July. Neither event legalises compounding. The PCAC vote is non-binding, and formal rulemaking takes a minimum of 12–18 months.

Both failure modes are documented and occurring simultaneously in 2026. Independent laboratory testing of black-market peptide vials has found products with active-ingredient concentrations up to double the labeled dose — a direct overdose risk — while other vials from the same market contained none of the advertised peptide at all. Neither outcome is detectable without analytical chemistry.

A 2026 Scientific Reports study and a companion IJMS critical review document that BPC-157 attenuates skeletal muscle ischemia-reperfusion injury in rats by reducing malondialdehyde, upregulating superoxide dismutase and catalase activity, suppressing caspase-3-mediated apoptosis, and preserving microvascular endothelial integrity — mechanisms that converge with the Yuan 2026 IJMS review's account of BPC-157's pro-angiogenic and cytoprotective signalling across tissue types.